Výsledky vyhledávání - "Alphonse, Hubsch"

Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations

Autor: Hillary Cuesta, Ibrahim El Menyawi, Alphonse Hubsch, Liane Hoefferer, Orell Mielke, Susie Gabriel, Amgad Shebl

Publikováno v: Transfusion. 62(9)

Severe hemolysis rarely occurs in patients receiving intravenous immunoglobulin (IVIG) therapy. A systematic review was performed to assess the incidence of IVIG-related hemolysis and the impact of patient and product risk factors.A systematic litera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43b06b957bb5cb567972c1cea9ca3e1
https://pubmed.ncbi.nlm.nih.gov/35916266

Zobrazit plný text záznamu

Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

Autor: Amgad Shebl, Susan Welsh, Alphonse Hubsch, John-Philip Lawo, Kristy Van Dinther, Susie Gabriel, Liane Hoefferer

Publikováno v: Transfusion

Background Hemolysis is an infrequent but recognized and potentially serious adverse effect of intravenous immunoglobulin (IVIG). Relatively elevated hemolysis reporting rates were seen with some IVIG products with high anti-A/B isoagglutinin content

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4257142f2b30f2076751e46fb83f2221
http://europepmc.org/articles/PMC7383922

Zobrazit plný text záznamu

Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study

Autor: Toby L. Simon, Alphonse Hubsch, Amgad Shebl, Christopher Wallenhorst, Ami Patel, Carlos Martinez

Publikováno v: Transfusion

BACKGROUND Intravenous immunoglobulins (IVIG) are derived from large human plasma pools. IVIG‐associated hemolytic anemia (HA) is a known class effect, likely attributed to dose‐dependent passive transfer of anti‐A/B isoagglutinins. Two isoaggl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad3a88c0b4c3f992c9f18dc722f455a
https://pubmed.ncbi.nlm.nih.gov/32488887

Zobrazit plný text záznamu

Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti‐A/B immunoaffinity chromatography and to a lesser extent with anti‐A donor screening

Autor: Alphonse Hubsch, Rajiv Mallick, David G. Barnes

Publikováno v: Transfusion. 58:2752-2756

Background The risk of hemolytic events (HEs) with intravenous immunoglobulin (IVIG) therapy appears to be linked to isoagglutinins (anti-A and anti-B) in the product. Patient risk factors include high IVIG dose, blood group, and underlying inflammat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7450c6cad920f14888044a682694a17a
https://doi.org/10.1111/trf.14918

Zobrazit plný text záznamu

Autor: Alphonse Hubsch, Abdulgabar Salama, Stefano Fontana, Orell Mielke, Vesselina Goranova-Marinova, Sandra Wymann, Billie L. Durn, Martin O. Spycher, John P. Lawo, Amgad Shebl

Publikováno v: Transfusion. 57:2629-2638

BACKGROUND Patients treated with intravenous immunoglobulins (IVIG) rarely experience symptomatic hemolysis. Although anti-A and anti-B isoagglutinins from the product are involved in most cases, the actual mechanisms triggering hemolysis are unclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7e75242fe10184069364ce48c801e57
https://doi.org/10.1111/trf.14289

Zobrazit plný text záznamu

Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry

Autor: Amgad Shebl, Dominik Stadler, Marc Bürzle, Nicole Spiegl, A. Adriano Marques, Thomas Roten, Lukas Martig, Alphonse Hubsch

Publikováno v: Analytical biochemistry. 591

Isoagglutinins present in intravenous immunoglobulin (IVIG) products have been linked to haemolysis. Therefore, accurately assessing isoagglutinin content in IVIG products is important. The standard European Pharmacopoeia (Ph.Eur.) direct assay is li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6903c9271f0ed200f03a88f27a88b4
https://pubmed.ncbi.nlm.nih.gov/31821802

Zobrazit plný text záznamu

Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

Autor: Annette Gaida, Nicole Spiegl, Alphonse Hubsch, Martin Imboden, Adriano Marques Antunes, Brigitte Zurbriggen, Simon Gerber, Sandra Wymann, Ibrahim El Menyawi

Publikováno v: Biodrugs

Background Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the presence of antibodies to blood groups A and B (isoagglutinins) in the IVIG product. An immunoaffinity chromatograp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8366a5fa741d1c47525c949ea709a92a
https://doi.org/10.1007/s40259-016-0192-3

Zobrazit plný text záznamu

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency

Autor: Alphonse Hubsch, John-Philip Lawo, Mikhail Rojavin

Publikováno v: Journal of Clinical Immunology

Purpose Intravenous IgG (IVIG) treatment wear-off is commonly experienced by patients, who report increased susceptibility to infection, and decreased quality of life towards the end of their 3- or 4-week dosing cycle, when serum IgG levels approach

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72958795bfeb404871105a08bc9c457f
https://doi.org/10.1007/s10875-016-0243-z

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání